These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 32981820)
1. Metabolic predictors for mortality among patients treated with long-term clozapine - A longitudinal study. Taub S; Hoshen M; Balicer R; Kamhi-Nesher S; Weizman A; Krivoy A Eur Neuropsychopharmacol; 2020 Dec; 41():63-69. PubMed ID: 32981820 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. Kelly DL; McMahon RP; Liu F; Love RC; Wehring HJ; Shim JC; Warren KR; Conley RR J Clin Psychiatry; 2010 Mar; 71(3):304-11. PubMed ID: 20079332 [TBL] [Abstract][Full Text] [Related]
3. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Tiihonen J; Lönnqvist J; Wahlbeck K; Klaukka T; Niskanen L; Tanskanen A; Haukka J Lancet; 2009 Aug; 374(9690):620-7. PubMed ID: 19595447 [TBL] [Abstract][Full Text] [Related]
4. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. Henderson DC; Nguyen DD; Copeland PM; Hayden DL; Borba CP; Louie PM; Freudenreich O; Evins AE; Cather C; Goff DC J Clin Psychiatry; 2005 Sep; 66(9):1116-21. PubMed ID: 16187768 [TBL] [Abstract][Full Text] [Related]
5. Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine. Feng S; Melkersson K Neuro Endocrinol Lett; 2012; 33(5):493-8. PubMed ID: 23090266 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular disease in patients with schizophrenia. Kritharides L; Chow V; Lambert TJ Med J Aust; 2017 Feb; 206(2):91-95. PubMed ID: 28152356 [TBL] [Abstract][Full Text] [Related]
7. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses. Kelly AC; Sheitman BB; Hamer RM; Rhyne DC; Reed RM; Graham KA; Rau SW; Gilmore JH; Perkins DO; Peebles SS; VanderZwaag CJ; Jarskog LF J Clin Psychopharmacol; 2014 Aug; 34(4):441-5. PubMed ID: 24943389 [TBL] [Abstract][Full Text] [Related]
8. Metabolic syndrome in schizophrenia - who is more to blame: FGA polypharmacy or clozapine monotherapy? Softic R; Sutovic A; Avdibegovic E; Osmanović E; Bećirović E; Hajdukov MM Psychiatr Danub; 2015 Dec; 27(4):378-84. PubMed ID: 26609650 [TBL] [Abstract][Full Text] [Related]
9. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Henderson DC; Cagliero E; Copeland PM; Borba CP; Evins AE; Hayden D; Weber MT; Anderson EJ; Allison DB; Daley TB; Schoenfeld D; Goff DC Arch Gen Psychiatry; 2005 Jan; 62(1):19-28. PubMed ID: 15630069 [TBL] [Abstract][Full Text] [Related]
10. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Lund BC; Perry PJ; Brooks JM; Arndt S Arch Gen Psychiatry; 2001 Dec; 58(12):1172-6. PubMed ID: 11735847 [TBL] [Abstract][Full Text] [Related]
11. Use of cardiovascular and antidiabetic drugs before and after starting with clozapine versus other antipsychotic drugs: a Dutch database study. van der Zalm Y; Termorshuizen F; Sommer IE; Selten JP Int Clin Psychopharmacol; 2020 Jan; 35(1):36-41. PubMed ID: 31714320 [TBL] [Abstract][Full Text] [Related]
12. Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis. Suetani RJ; Siskind D; Reichhold H; Kisely S Psychopharmacology (Berl); 2017 Oct; 234(20):2989-3008. PubMed ID: 28879574 [TBL] [Abstract][Full Text] [Related]
13. Risk of New-Onset Diabetes After Long-Term Treatment With Clozapine in Comparison to Other Antipsychotics in Patients With Schizophrenia. Schulte PF; Bocxe JT; Doodeman HJ; van Haelst IM; Cohen D J Clin Psychopharmacol; 2016 Apr; 36(2):115-9. PubMed ID: 26872114 [TBL] [Abstract][Full Text] [Related]
14. Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years. Vermeulen JM; van Rooijen G; van de Kerkhof MPJ; Sutterland AL; Correll CU; de Haan L Schizophr Bull; 2019 Mar; 45(2):315-329. PubMed ID: 29697804 [TBL] [Abstract][Full Text] [Related]
15. Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia. Eskelinen S; Sailas E; Joutsenniemi K; Holi M; Suvisaari J Nord J Psychiatry; 2015 Jul; 69(5):339-45. PubMed ID: 25981178 [TBL] [Abstract][Full Text] [Related]
16. Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis. Zhang C; Zhang Y; Cai J; Chen M; Song L Pharmacogenomics J; 2017 Jan; 17(1):92-97. PubMed ID: 26503818 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia. Pridan S; Swartz M; Baruch Y; Tadger S; Plopski I; Barak Y Int Psychogeriatr; 2015 Jan; 27(1):131-4. PubMed ID: 25166892 [TBL] [Abstract][Full Text] [Related]
18. Metabolic syndrome and cardiovascular risk between clozapine and non-clozapine antipsychotic users with schizophrenia. Quek YF; See YM; Yee JY; Rekhi G; Ng BT; Tang C; Lee J Asian J Psychiatr; 2022 Aug; 74():103192. PubMed ID: 35751958 [TBL] [Abstract][Full Text] [Related]
19. Parental history of diabetes mellitus has additive risk of metabolic syndrome in patients treated with clozapine. Zeng Y; Chen S; Liu D; Hahn L; Xia X; Wen S; Han Z; Wu X Asian J Psychiatr; 2020 Apr; 50():101939. PubMed ID: 32087501 [No Abstract] [Full Text] [Related]